TSX gains after CPI shows US inflation rose 3%
FRANKLIN LAKES, N.J. - Medical technology company BD (NYSE:BDX), a $54.2 billion healthcare equipment leader with robust annual revenue of $21.39 billion and steady 7.86% growth, announced on Monday the introduction of its new BD Incada Connected Care Platform, an AI-enabled cloud-based system designed to unify data from the company’s medical devices. According to InvestingPro analysis, BD maintains a GOOD financial health score, positioning it well for continued innovation.
The platform, built on Amazon Web Services infrastructure, is now available alongside the launch of BD’s next-generation Pyxis Pro Automated Medication Dispensing Solution, according to a company press release.
The new system aims to provide enterprise-wide visibility by connecting data from various medical devices including infusion pumps, patient monitors, and pharmacy robotics. The platform leverages AI technologies such as natural language search in analytics and can handle data from nearly 3 million connected BD devices.
The Pyxis Pro Dispensing Solution offers expanded medication storage capacity, allowing hospitals to add up to 538 multi-access or 98 secure pockets without requiring additional space. The system includes enhanced security features for controlled substance management and efficiency improvements like RFID badge scanning and illuminated bins.
"With the enhanced secure capacity, durability and AI-powered analytics of the next-generation BD Pyxis Pro Dispensing Solution, we’re ushering in a transformative new era for medication management," said Connor Bates, Worldwide President for Medication Management Solutions at BD, in the statement.
The company reports that its existing Pyxis System handles more than 9.8 million transactions daily across hospitals and health systems.
BD, which employs over 70,000 people globally, focuses on developing technologies to improve medical discovery, diagnostics, and care delivery across virtually every country worldwide. The company has demonstrated remarkable stability, maintaining dividend increases for 54 consecutive years, and currently trades below its InvestingPro Fair Value, suggesting potential upside opportunity for investors. Discover more insights and metrics with InvestingPro, where additional ProTips reveal key investment considerations for BD’s stock.
In other recent news, Becton Dickinson announced disappointing preliminary fourth-quarter sales results, falling below consensus estimates. Additionally, the company revealed that its Chief Financial Officer, Chris DelOrefice, will depart on December 5 to pursue another opportunity. RBC Capital noted that the preliminary revenue and earnings per share for the fiscal fourth quarter came in slightly below the low end of its previous guidance. In terms of analyst coverage, RBC Capital reiterated its Sector Perform rating on Becton Dickinson stock. The company also enrolled the first patient in its XTRACT Registry study, aimed at evaluating the Rotarex Catheter System’s performance in treating peripheral artery disease. Furthermore, Becton Dickinson has partnered with Opentrons Labworks to automate single-cell research workflows, integrating robotic liquid-handling capabilities into its instruments. This collaboration seeks to enhance disease research and drug development processes. Lastly, RBC Capital initiated coverage on Becton Dickinson with a Sector Perform rating, highlighting the company’s plans to spin off and merge its Biosciences and Diagnostics businesses with Waters in early 2026.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.